Drug intelligence / Profile preview

chloroquine + nab-paclitaxel

Development stage: Phase 2
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of chloroquine and nab-paclitaxel. Chloroquine is an antimalarial drug that has been repurposed to target cancer stem cells (CSCs) and inhibit autophagy, a cellular process that can lead to chemotherapy resistance. Nab-paclitaxel is a taxane-based chemotherapy agent that promotes assembly and stabilization of microtubules from tubulin dimers, inhibiting cell replication by blocking the G2 mitotic phase. This combination has been studied in clinical trials for advanced or metastatic breast cancer and pancreatic cancer.

Targets

ALB (Human serum albumin)SLC47A1 (Multidrug and toxin extrusion transporter 1)MRP (Multidrug resistance-associated protein family)NeuraminidaseTUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on chloroquine + nab-paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chloroquine + nab-paclitaxel.